Perrigo Company plc News
Perrigo Shares Off on Swing to Loss, Lagging Adjusted Profit
Perrigo's third-quarter adjusted earnings totaled 45 cents a share, beneath the FactSet analyst consensus of 65 cents. The stock is lower.
5 Top Stock Gainers for Thursday: Paychex, Virgin Galactic, Perrigo
Paychex, Virgin Galactic, Perrigo, Splunk and Lordstown Motors are five top stock gainers for Thursday.
Perrigo Stock Jumps After Settling Irish Tax Dispute
Perrigo stock climbs as the drugmaker agreed to a tax settlement to avoid the risks of litigation and ongoing legal costs.
Perrigo Agrees to Buy Hera for $2.1 Billion in Cash
Perrigo is buying Hera from funds affiliated with private equity firm Astorg and Goldman Sachs Asset Management.
Five Top Stock Gainers for Tuesday: Match, Spotify, Netflix
Match Group, Spotify, Netflix, Columbia Property Trust and Cirrus Logic are five top stock gainers for Tuesday.
Match Group Stock Surges As Tinder Dating App Owner Added To S&P 500
Tinder owner Match Group will join the S&P 500 on Monday September 20, replacing Dublin, Ireland-based Perrigo Co.
S&P 500 Index Adding Ceridian, Brown & Brown and Match Group
Broad market index dropping Unum, NOV and Perrigo in quarterly review.
Perrigo Stock Lower; Results Hurt by Weak Cough-and-Cold Season
Perrigo swung to a second-quarter loss from a year-earlier profit, hurt by a weak cough-and-cold season. The stock is lower.
Perrigo Sells Generic Drug Unit to Altaris Capital for $1.55 Billion
Last year, state and local attorneys general sued Perrigo and other drug companies for artificially inflating prices of 80 generic drugs.
State Attorneys General Sue Generic Drugmakers for Inflating Prices
Mylan, Teva, Taro and Perrigo are among those accused of price-fixing, market allocation and bid-rigging on 80 topical drugs.
Trump's Potential Return to Twitter Under Musk Hits Digital World
Digital World Acquisition, a company attempting to merge with former President Donald Trump's media group Truth Social, faces a new challenge.
Bluebird Bio's 2nd Approval Doesn't Guarantee Survival
Investors hoping for a revival at the struggling biotech might want to temper their expectations.